Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307749

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1307749

APAC Pemphigus Vulgaris Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The Asia-Pacific pemphigus vulgaris market is expected to reach USD 115.59 million by 2030 from USD 57.14 million in 2022, growing at a CAGR of 9.3% during the forecast period of 2023 to 2030.

Market Segmentation:

Asia-Pacific Pemphigus Vulgaris Market, By Diagnosis and Treatment (Diagnosis, Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Pemphigus Vulgaris Market Dynamics:

  • Driver
  • Rise in patients with rare diseases such as pemphigus vulgaris
  • Restraint
  • High cost of treatment
  • Opportunity
  • Rising healthcare facilities in the developing and underdeveloped countries

Market Players

The key market players operating in the market are:

  • Johnson & Johnson Services, Inc.
  • RAKSHIT DRUGS PVT. LTD
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Celltrion Healthcare Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Lilly
  • Zydus Group
  • GSK plc.

TABLE OF CONTENTS

1 INTRODUCTION 31

  • 1.1 OBJECTIVES OF THE STUDY 31
  • 1.2 MARKET DEFINITION 31
  • 1.3 OVERVIEW 31
  • 1.4 CURRENCY AND PRICING 33
  • 1.5 LIMITATIONS 33
  • 1.6 MARKETS COVERED 33

2 MARKET SEGMENTATION 36

  • 2.1 MARKETS COVERED 36
  • 2.2 GEOGRAPHICAL SCOPE 37
  • 2.3 YEARS CONSIDERED FOR THE STUDY 38
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
  • 2.6 MULTIVARIATE MODELLING 43
  • 2.7 MARKET APPLICATION COVERAGE GRID 44
  • 2.8 PRODUCT LIFELINE CURVE 45
  • 2.9 DBMR MARKET POSITION GRID 46
  • 2.10 VENDOR SHARE ANALYSIS 47
  • 2.11 SECONDARY SOURCES 48
  • 2.12 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

  • 4.1 PESTEL ANALYSIS 52
  • 4.2 PORTER FIVE FORCES 53
  • 4.3 PATENT ANALYSIS 54
  • 4.4 PATIENT FLOW DIAGRAM 55
  • 4.5 KEY PRICING STRATEGIES 56
  • 4.6 FUTURE THERAPIES 57
  • 4.7 KEY PATIENT ENROLLMENT STRATEGIES 58

5 PIPELINE ANALYSIS 59

6 EPIDEMIOLOGY 60

7 INDUSTRY INSIGHTS 61

8 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: REGULATIONS 62

9 MARKET OVERVIEW 65

  • 9.1 DRIVERS 67
    • 9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
    • 9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
    • 9.1.3 AWARENESS REGARDING THE DISEASE 68
  • 9.2 RESTRAINTS 68
    • 9.2.1 STRICT REGULATORY GUIDELINES 68
    • 9.2.2 HIGH TREATMENT COSTS 68
  • 9.3 OPPORTUNITIES 69
    • 9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
    • 9.3.2 INCREASING HEALTHCARE FACILITIES 69
    • 9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
  • 9.4 CHALLENGES 70
    • 9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
    • 9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71

10 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72

  • 10.1 OVERVIEW 73
  • 10.2 TREATMENT 76
    • 10.2.1 MEDICATIONS, BY TYPE 76
      • 10.2.1.1 CORTICOSTEROIDS 77
      • 10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
        • 10.2.1.2.1 AZATHIOPRINE 78
        • 10.2.1.2.2 MYCOPHENALATE MOFETIL 78
        • 10.2.1.2.3 METHOTREXATE 78
        • 10.2.1.2.4 CYCLOPHOSPHAMIDE 78
        • 10.2.1.2.5 MIZORIBINE 78
        • 10.2.1.2.6 OTHERS 78
      • 10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
        • 10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
        • 10.2.1.3.2 TETRACYCLINE 79
        • 10.2.1.3.3 OTHERS 79
      • 10.2.1.4 BIOLOGICS 79
      • 10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
      • 10.2.1.6 ANTIBIOTICS 79
      • 10.2.1.7 ANTIFUNGALS 79
      • 10.2.1.8 ANTIVIRALS 79
      • 10.2.1.9 OTHER MEDICATIONS 79
    • 10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
      • 10.2.2.1 ORAL 80
      • 10.2.2.2 TOPICAL 80
      • 10.2.2.3 PARENTERAL 80
      • 10.2.2.4 OTHERS 80
    • 10.2.3 MEDICATIONS, BY DRUG TYPE 80
      • 10.2.3.1 GENERIC 81
      • 10.2.3.2 BRANDED 81
  • 10.3 DIAGNOSIS 81
    • 10.3.1 SKIN BIOPSY 82
    • 10.3.2 BLOOD TEST 82
    • 10.3.3 ENDOSCOPY 82

11 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83

  • 11.1 OVERVIEW 84
  • 11.2 ADULTS 87
  • 11.3 GERIATRIC 88
  • 11.4 PEDIATRIC 89

12 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 90

  • 12.1 OVERVIEW 91
  • 12.2 HOSPITALS 94
  • 12.3 SPECIALTY CLINICS 94
  • 12.4 RESEARCH INSTITUTES 95
  • 12.5 OTHERS 96

13 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97

  • 13.1 OVERVIEW 98
  • 13.2 HOSPITALS PHARMACY 101
  • 13.3 RETAIL PHARMACY 101
  • 13.4 ONLINE PHARMACY 102

14 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY REGION 103

  • 14.1 ASIA-PACIFIC 104
    • 14.1.1 CHINA 113
    • 14.1.2 INDIA 117
    • 14.1.3 SOUTH KOREA 121
    • 14.1.4 MALAYSIA 125
    • 14.1.5 JAPAN 129
    • 14.1.6 AUSTRALIA 133
    • 14.1.7 SINGAPORE 137
    • 14.1.8 THAILAND 141
    • 14.1.9 INDONESIA 145
    • 14.1.10 PHILIPPINES 149
    • 14.1.11 REST OF ASIA-PACIFIC 152

15 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 153

  • 15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 153

16 SWOT ANALYSIS 154

17 COMPANY PROFILE 155

  • 17.1 ABBVIE INC. 155
    • 17.1.1 COMPANY SNAPSHOT 155
    • 17.1.2 REVENUE ANALYSIS 155
    • 17.1.3 COMPANY SHARE ANALYSIS 156
    • 17.1.4 PRODUCT PORTFOLIO 156
    • 17.1.5 RECENT DEVELOPMENTS 157
  • 17.2 MERCK & CO., INC., 158
    • 17.2.1 COMPANY SNAPSHOT 158
    • 17.2.2 REVENUE ANALYSIS 158
    • 17.2.3 COMPANY SHARE ANALYSIS 159
    • 17.2.4 PRODUCT PORTFOLIO 159
    • 17.2.5 RECENT DEVELOPMENT 159
  • 17.3 SANOFI 160
    • 17.3.1 COMPANY SNAPSHOT 160
    • 17.3.2 REVENUE ANALYSIS 160
    • 17.3.3 COMPANY SHARE ANALYSIS 161
    • 17.3.4 PRODUCT PORTFOLIO 161
    • 17.3.5 RECENT DEVELOPMENT 161
  • 17.4 REGENERON PHARMACEUTICALS INC. 162
    • 17.4.1 COMPANY SNAPSHOT 162
    • 17.4.2 REVENUE ANALYSIS 162
    • 17.4.3 COMPANY SHARE ANALYSIS 163
    • 17.4.4 PRODUCT PORTFOLIO 163
    • 17.4.5 RECENT DEVELOPMENT 163
  • 17.5 NOVARTIS AG 164
    • 17.5.1 COMPANY SNAPSHOT 164
    • 17.5.2 REVENUE ANALYSIS 164
    • 17.5.3 COMPANY SHARE ANALYSIS 165
    • 17.5.4 PRODUCT PORTFOLIO 165
    • 17.5.5 RECENT DEVELOPMENT 165
  • 17.6 AMGEN INC. 166
    • 17.6.1 COMPANY SNAPSHOT 166
    • 17.6.2 REVENUE ANALYSIS 166
    • 17.6.3 PRODUCT PORTFOLIO 167
    • 17.6.4 RECENT DEVELOPMENTS 167
  • 17.7 ASTRAZENECA 168
    • 17.7.1 COMPANY SNAPSHOT 168
    • 17.7.2 REVENUE ANALYSIS 168
    • 17.7.3 COMPANY SHARE ANALYSIS 169
    • 17.7.4 PRODUCT PORTFOLIO 169
    • 17.7.5 RECENT DEVELOPMENTS 170
  • 17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 171
    • 17.8.1 COMPANY SNAPSHOT 171
    • 17.8.2 REVENUE ANALYSIS 171
    • 17.8.3 PRODUCT PORTFOLIO 172
    • 17.8.4 RECENT DEVELOPMENT 172
  • 17.9 CELLTRION HEALTHCARE CO., LTD 173
    • 17.9.1 COMPANY SNAPSHOT 173
    • 17.9.2 REVENUE ANALYSIS 173
    • 17.9.3 PRODUCT PORTFOLIO 174
    • 17.9.4 RECENT DEVELOPMENTS 174
  • 17.10 F. HOFFMANN- LA ROCHE LTD. 175
    • 17.10.1 COMPANY SNAPSHOT 175
    • 17.10.2 REVENUE ANALYSIS 175
    • 17.10.3 PRODUCT PORTFOLIO 176
    • 17.10.4 RECENT DEVELOPMENT 176
  • 17.11 FRESENIUS KABI AG 177
    • 17.11.1 COMPANY SNAPSHOT 177
    • 17.11.2 REVENUE ANALYSIS 177
    • 17.11.3 PRODUCT PORTFOLIO 178
    • 17.11.4 RECENT DEVELOPMENT 178
  • 17.12 GSK PLC 179
    • 17.12.1 COMPANY SNAPSHOT 179
    • 17.12.2 REVENUE ANALYSIS 179
    • 17.12.3 PRODUCT PORTFOLIO 180
    • 17.12.4 RECENT DEVELOPMENT 180
  • 17.13 JOHNSON & JOHNSON SERVICES, INC. 181
    • 17.13.1 COMPANY SNAPSHOT 181
    • 17.13.2 REVENUE ANALYSIS 181
    • 17.13.3 COMPANY SHARE ANALYSIS 182
    • 17.13.4 PRODUCT PORTFOLIO 182
    • 17.13.5 RECENT DEVELOPMENT 182
  • 17.14 LILLY 183
    • 17.14.1 COMPANY SNAPSHOT 183
    • 17.14.2 REVENUE ANALYSIS 183
    • 17.14.3 PRODUCT PORTFOLIO 184
    • 17.14.4 RECENT DEVELOPMENT 184
  • 17.15 PFIZER INC. 185
    • 17.15.1 COMPANY SNAPSHOT 185
    • 17.15.2 REVENUE ANALYSIS 185
    • 17.15.3 PRODUCT PORTFOLIO 186
    • 17.15.4 RECENT DEVELOPMENT 186
  • 17.16 RAKSHIT DRUGS PVT. LTD 187
    • 17.16.1 COMPANY SNAPSHOT 187
    • 17.16.2 PRODUCT PORTFOLIO 187
    • 17.16.3 RECENT DEVELOPMENT 187
  • 17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 188
    • 17.17.1 COMPANY SNAPSHOT 188
    • 17.17.2 REVENUE ANALYSIS 188
    • 17.17.3 PRODUCT PORTFOLIO 189
    • 17.17.4 RECENT DEVELOPMENT 189
  • 17.18 ZYDUS GROUP 190
    • 17.18.1 COMPANY SNAPSHOT 190
    • 17.18.2 REVENUE ANALYSIS 190
    • 17.18.3 PRODUCT PORTFOLIO 191
    • 17.18.4 RECENT DEVELOPMENT 191

18 QUESTIONNAIRE 192

19 RELATED REPORTS 194

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS 42
  • TABLE 2 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, PIPELINE ANALYSIS 47
  • TABLE 3 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 63
  • TABLE 4 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
  • TABLE 5 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 6 ASIA PACIFIC STEROID- SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 7 ASIA PACIFIC ANTI- INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 66
  • TABLE 8 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 68
  • TABLE 9 ASIA PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 68
  • TABLE 10 ASIA PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 11 ASIA PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 70
  • TABLE 12 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 74
  • TABLE 13 ASIA PACIFIC ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 14 ASIA PACIFIC GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
  • TABLE 15 ASIA PACIFIC PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 16 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 81
  • TABLE 17 ASIA PACIFIC HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 18 ASIA PACIFIC SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 19 ASIA PACIFIC RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 20 ASIA PACIFIC OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 21 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 88
  • TABLE 22 ASIA PACIFIC HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 23 ASIA PACIFIC RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 24 ASIA PACIFIC ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 25 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 96
  • TABLE 26 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 96
  • TABLE 27 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 28 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 29 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 30 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 98
  • TABLE 31 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 32 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 33 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 34 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 99
  • TABLE 35 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 100
  • TABLE 36 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 101
  • TABLE 37 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 38 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 39 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 40 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 102
  • TABLE 41 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 42 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 43 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 44 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 103
  • TABLE 45 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 104
  • TABLE 46 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 105
  • TABLE 47 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 48 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 49 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 50 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 106
  • TABLE 51 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 52 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 53 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 54 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 107
  • TABLE 55 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 108
  • TABLE 56 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 109
  • TABLE 57 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 58 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 59 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 60 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 110
  • TABLE 61 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 62 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 63 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 64 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
  • TABLE 65 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 112
  • TABLE 66 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 113
  • TABLE 67 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 68 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 69 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 70 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 114
  • TABLE 71 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 72 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 73 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 74 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 116
  • TABLE 75 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 116
  • TABLE 76 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 117
  • TABLE 77 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 78 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 79 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 80 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 118
  • TABLE 81 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 118
  • TABLE 82 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 83 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 84 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 119
  • TABLE 85 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 120
  • TABLE 86 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 121
  • TABLE 87 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 88 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 89 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 90 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 122
  • TABLE 91 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 92 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 93 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 94 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
  • TABLE 95 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 124
  • TABLE 96 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 125
  • TABLE 97 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 98 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 99 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 100 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 126
  • TABLE 101 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 102 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 103 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 104 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 128
  • TABLE 105 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 128
  • TABLE 106 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 129
  • TABLE 107 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 108 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 109 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
  • TABLE 110 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 130
  • TABLE 111 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 112 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 113 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 114 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 132
  • TABLE 115 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
  • TABLE 116 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 133
  • TABLE 117 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 118 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 119 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 120 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 134
  • TABLE 121 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 122 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 123 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 124 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
  • TABLE 125 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
  • TABLE 126 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 137
  • TABLE 127 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 128 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 129 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 130 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 138
  • TABLE 131 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 132 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 133 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 134 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2021-2030 (USD MILLION) 139
  • TABLE 135 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 139
  • TABLE 136 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2021-2030 (USD MILLION) 140

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: SEGMENTATION 23
  • FIGURE 2 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION 26
  • FIGURE 3 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS 27
  • FIGURE 4 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 28
  • FIGURE 5 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS 28
  • FIGURE 6 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS 29
  • FIGURE 7 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: MARKET APPLICATION COVERAGE GRID 31
  • FIGURE 8 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID 33
  • FIGURE 9 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS 34
  • FIGURE 10 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: SEGMENTATION 37
  • FIGURE 11 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARISIS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC PEMPHIGUS VULGARIS MARKET FROM 2023 TO 2030 38
  • FIGURE 12 THE DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC PEMPHIGUS VULGARIS MARKET IN 2023 AND 2030 38
  • FIGURE 13 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:- 42
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC PEMPHIGUS VULGARIS MARKET 53
  • FIGURE 15 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2022 60
  • FIGURE 16 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2023-2030 (USD MILLION) 61
  • FIGURE 17 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2023-2030) 61
  • FIGURE 18 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE 62
  • FIGURE 19 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2022 71
  • FIGURE 20 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION) 72
  • FIGURE 21 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2023-2030) 72
  • FIGURE 22 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE 73
  • FIGURE 23 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, 2022 78
  • FIGURE 24 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, 2023-2030 (USD MILLION) 79
  • FIGURE 25 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2023-2030) 79
  • FIGURE 26 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE 80
  • FIGURE 27 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2022 85
  • FIGURE 28 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 86
  • FIGURE 29 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 86
  • FIGURE 30 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 87
  • FIGURE 31 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2022) 92
  • FIGURE 32 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022) 93
  • FIGURE 33 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2023 & 2030) 93
  • FIGURE 34 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: BY COUNTRY (2022 & 2030) 94
  • FIGURE 35 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: DIAGNOSIS AND TREATMENT (2023-2030) 94
  • FIGURE 36 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2022 (%) 140
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!